



Рус.

UDK 615.225:611.018.74

DOI: 10.18413/2313-8971-2016-2-2-36-40

Khadieva T.A.¹
Dovgan A. P.²
Pokroskaya T.G.³

METHOD OF CORRECTION OF ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF ADEMETIONINE AND TAURINE

- 1) Therapist, supervisor of the receiving department of the central city hospital in Khasavyurt 21, Aliyev st., Khasavyurt, Russia, 368004/ e-mail: khadievoi91@mail.ru
- 2) PhD 2nd year student of pharmacology department of medical institute «BelGU» 85, Pobidy st., Belgorod, Russia, 308005/ e-mail: dr.dovgan@mail.ru
- 3) M.D., professor of pharmacology department of medical institute «BelGU» 85, Pobidy, 85, Belgorod, Russia, 308005/ e-mail: pokrovskaya-tg@mail.ru

Abstract. In the experiment, was made a simulation of endothelial dysfunction in male rats of Wistar-line by intraperitoneal administration of L-NAME at a dose of 25 mg/kg/day for 7 days. Deficiency of nitric oxide in result of the blockade of NO-synthase was accompanied by violation of endothelium-dependent and endothelium-independent vasodilation assessed in pharmacological trials, which was reflected in the increase of the coefficient endothelial dysfunction. In this case, for correction of endothelial dysfunction intraperitoneally ademetonine in the dose of 150 mg/kg and after an hour taurine at a dose of 260 mg/kg was injected the animal once a day for 7 days.

The method provides effective impact of the combination of hepatoprotector Ademetonine in the dose of 150 mg/kg/day and a sulfur-containing amino acid Taurine in the dose of 260 mg/kg/day on the functioning of the vascular endothelium, and has endotheliopathy effect on models L-NAME-induced deficiency of nitric oxide, which includes the endothelium-dependent vasodilation and the decrease of coefficient of endothelial dysfunction.

Keywords: L-NAME, endothelial dysfunction, taurine, ademetonine, nitric oxide, oxidative stress.

Intro: As already known, the endothelium maintains homeostasis by regulating the balance of opposing processes: vascular tone, responsible for vasodilation and vasoconstriction; anatomical structure of blood vessels, regulating the synthesis and the inhibition factors of cell proliferation; hemostasis, participating in the synthesis and inhibition of fibrinolysis factors and platelet aggregation; local inflammation by producing Pro- and anti-inflammatory cytokines [1, 2, 3, 4]. The endothelium lines all vessels, regardless of their organ localization, so endothelial dysfunction, the basis of which is reduced synthesis of endothelial cell nitric oxide (NO) is a predictor of diseases, not only arteries and veins, but components of the microvasculature [5, 6]. Endothelial dysfunction explains the pathogenesis of diseases such as hypertension, atherosclerosis, coronary artery disease, cardiomyopathy, pathogenesis of chronic heart failure, metabolic disorders: hyperlipidemia, hyperhomocysteinemia, hypoestrogenemia, diabetic vascular lesions, venous transformation [7, 8, 9, 10]. Therefore, the goal of our research was the search of drugs, their combinations are capable of correcting endothelial dysfunction, having endotheliopathy

effect. From the literature it is known that taurine has antihypertensive, antioxidant [11] activities, contributes to endothelium-independent vasodilation [12], the lack of endogenous taurine inhibits the processes of vasorelaxation [13].

Endothelial dysfunction is a prerequisite for the development of atherosclerosis.

It is known that under the action of ademetonine normalization coefficient of endothelial dysfunction and that treatment with S-adenosyl-1-methionine (SAM) prevents endothelial dysfunction in animals by induction of hemoxygenase-1 (HO-1) in endothelial cells of blood vessels and I believe that treatment (CAM) may represent a new therapeutic strategy for atherosclerosis [14, 15].

Main part: In connection with the foregoing, the purpose of this study was the investigation the endotheliopathy properties of a combination of ademetonine in the dose of 150 mg/kg/day and taurine at a dose of 260 mg/kg/day as one of the possible effective combinations with dysfunction of endothelium, L-NAME-induced [16, 17, 18] deficiency of nitric oxide.

Materials and methods research. Experiments were carried out on white rats-males of Wistar-line

weighing 170-220 g. (n=10 animals). L-NAME was injected intraperitoneally at a dose of 25 mg/kg/day. Ademetonine and taurine and their combination are entered daily intragastrically (by gavage) at doses of 150 mg/kg/day and 260 mg/kg/day accordingly, at intervals of an hour, for 7 days. On the eighth day from the beginning of the experiment under combined anesthesia (chloralhydrate 150 mg/kg and zoletile 60 mg/kg) was injected a catheter in the left carotid artery for registration of blood pressure (BP), vascular samples was carried out by introduction of a bolus into the left femoral vein of pharmacological agents. Hemodynamic parameters: systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR), measured continuously by a sensor TSD104A and hardware-software complex MP100, production Biopac System, Inc., USA. Functional tests: endothelium-dependent vasodilation (EDV) – intravenous administration of acetylcholine (AH) at a dose of 40 mg/kg, endothelium-independent vasodilation (EIV) – intravenous injection of nitroprusside sodium (NP) at a dose of 30 µg/kg.

To assess the degree of endothelial dysfunction in experimental animals and its correction by researched drugs we have performed the calculation of the coefficient of endothelial dysfunction (CED) [16, 17, 18, 19].

With statistical data processing was calculated average value, standard deviation. The differences were considered significant at $p < 0.05$. The normality of distribution was checked using the Shapiro-Wilk test.

The results of research and their discussion: Arterial pressure in intact males were:

systolic (SBP) – over 139.0 ± 3.5 mm Hg, diastolic (DBP) – 105.0 ± 2.9 mm Hg and HR - 420.0 ± 9.0 . The introduction of the blocker of NO-synthase, L-NAME, resulted in severe arterial hypertension (AH) (SBP – 190.3 ± 6.7 , DBP – 145.0 ± 3.9 mm Hg and HR – 428.0 ± 11.0) (Fig.1). During the simultaneous administration of L-NAME and ademetonine (150 mg/kg) was observed decreasing values of BP (SBP to 160.2 ± 12.6 , DBP to 124.3 ± 9.0 , MBP to 136.1 ± 10.2 mm. Hg), monotherapy with taurine (260 mg/kg) – (SBP to 158.2 ± 5.7 , DBP 122.9 ± 5.5 , MBP 134.3 ± 5.3 mm. Hg) and with combination of ademetonine and taurine with L-NAME induced deficiency of nitric oxide indicators was reduced to the following values – SBP to 146.5 ± 3.6 , DBP to 126.4 ± 3.0 , MBP to 133.6 ± 3.2 mm. Hg. Bolus intravenous injection of AH within 3-5 seconds decreased a blood pressure, reaching a peak in the intact animals for the SBP of 84.3 ± 1.6 for DBP of 38.7 ± 2.8 and for mean arterial pressure (MBP) 55.8 ± 1.7 mm. Hg while during the first 2-3 seconds developed sudden bradycardia up to 130-150 beats per minute. Restoring of the BP happened in average 42.2 ± 0.8 seconds after normalization of heart rate. EIV was also characterized by a decreasing of the SBP to 87.0 ± 2.8 , DBP to 42.1 ± 4.4 , MBP to 55.7 ± 3.5 mm Hg followed by full recovery within average 45.1 ± 1.0 sec. Blockade of NO-synthase with the help daily during the 7-day intraperitoneal injection of L-NAME at a dose of 25 mg/kg led to a smaller decline in BP after the introduction of AH (SBP to 110.6 ± 5.2 , DBP to 82.8 ± 6.6 , MBP to 92.1 ± 6.1 mm Hg) and NP (SBP to 88.7 ± 4.7 , DBP to 50.8 ± 4.2 , MBP to 63.4 ± 4.1 mm Hg) compared to the intact group. (table 1).

Table 1.

Dynamics of blood pressure parameters and heart rate in the simulation of deficiency of nitric oxide and correction of endothelial dysfunction

Animal group	Functional tests	DBP, mm Hg	DBP, mm Hg	HR, per minute
Intact	Source	139.0 ± 3.5	105.0 ± 2.9	420.0 ± 9.0
	AH	84.3 ± 1.6	38.7 ± 2.8	-
	NP	87.0 ± 2.8	42.1 ± 4.4	-
L-NAME (25 mg/kg)	Source	190.3 ± 6.7	145.0 ± 3.9	428.0 ± 11.0
	AH	110.6 ± 5.2	82.8 ± 6.6	
	NP	88.7 ± 4.7	50.8 ± 4.2	
L-NAME (25 mg/kg) + ademetonine (150 mg/kg)	Source	$160.2 \pm 12.6^*$	124.3 ± 9.0	320.5 ± 15.6
	AH	94.5 ± 5.6	66.0 ± 6.5	
	NP	83.5 ± 6.5	42.3 ± 2.1	
L-NAME (25 mg/kg) + taurine (260 mg/kg)	Source	158.2 ± 5.7	122.9 ± 5.5	317.5 ± 26.2
	AH	$113.8 \pm 1.8^*$	67.3 ± 2.4	
	NP	$111.6 \pm 3.4^*$	46.2 ± 1.8	
L-NAME (25 mg/kg) + ademetonine (150 mg/kg) + taurine (260 mg/kg)	Source	146.5 ± 3.6	126.4 ± 3.0	316.0 ± 20.5
	AH	88.8 ± 1.9	66.5 ± 2.4	
	NP	71.0 ± 3.8	46.0 ± 2.1	

$p < 0.05$ in comparison with the group L-NAME

* $p < 0.05$ in comparison with the group L-NAME + ademetonine + taurine

It was also noted potentiation of decrease in indicators of arterial pressure in response to the introduction of AH. The difference in EDV and EIV in the intact animals and animals with the introduction of the inhibitor of NO-synthase L-NAME leads to the determination of the coefficient of endothelial dysfunction (CED) as the ratio of the area of the triangle above the trend of the reduction BP reaction in response to the introduction of AH.

The CED is difference between intact group and the group treated with L-NAME in 5 times respectively of 1.2 and 5.2 in intact animals treated with L-NAME. (Pokrovskaya T.G. monography).

Thus, the obtained results allow us to conclude the activation of the correction of endothelial dysfunction with ademetonine in combined application with taurine (table 2).

Table 2

Dynamics of indicators that reflect the correction of endothelial dysfunction on the background of the introduction of L-NAME with ademetonine, taurine and their combination.

Animal group	Functional tests	The increase in the incidence of vascular response at Srad (mm Hg)	Time vascular reactions	Time vascular reactions	CED (the area ratio of vascular responses AH to NP)
L-NAME + адеметионин	АХ	60,8±5,2	27,4±3,7	803,5±97,0	4,6±0,5
	НП	91±8	76,8±5,1	3505,2±366,1	
L-NAME + таурин	АХ	51,9±4,5	19,7±2,1	519,2±67,9	4,3±0,7
	НП	67±4	56,1±5,1	1905,6±206,0	
L-NAME + адеметионин + таурин	АХ	59,2±2,0	41,3±7,1	1139,2±136,2	3,2±0,4*
	НП	78±4	83,3±2,4	3275,1±232,4	

*p<0,05 in comparison with the group L-NAMEademetonine+ taurine

Thus, the results demonstrate that investigational drugs have not only antihypertensive effect but also contribute to the reduction of the coefficient of

endothelial dysfunction in comparison with group L-NAME (Fig.1).




Figure 1. The values of the coefficient of endothelial dysfunction in correction with ademetonine (150 mg/kg/day), taurine (260 mg/kg/day) and their combination in comparison with the intact group and the group in modeling L-NAME (25 mg/kg intraperitoneally once daily for 7 days) induced NO deficit, *- p<0.05 compared with group L-NAME.

Conclusion: On models L-NAME-induced deficit of nitrogen oxide are realized antihypertensive, antioxidant and endothelioprotective properties of taurine and ademetonine, as according to the literature, inhibition of nitric oxide production in the application of L-NAME was accompanied by a significant increase in the spontaneous production of superoxide anion radical, hypertension and increase of coefficient of endothelial dysfunction [10, 20]. Hyperproduction of superoxide radical and its derivatives – oxygen radicals – is a mechanism for development of oxidative stress (OS), in which the suppression of the antioxidant defense system and increased formation of oxidation products, which are the factors for the formation of endothelial dysfunction [21, 22, 23]. In the study it was found that the combined using of ademetonine in the dose 150mg/kg/day and taurine at a dose of 260 mg/kg/day provides more endothelioprotective effect on models L-NAME-induced deficit of nitrogen oxide in comparison with monotherapy, which was reflected in the decrease of coefficient of endothelial dysfunction (CED) [24] and the BP values to a level close to the level of intact animals. Therefore, monotherapy endothelial dysfunction with ademetonine and taurine is regarded as insufficient, and leads to further search for more effective ways of pharmacotherapy, one of which is the combined application of taurine and ademetonine. From our point of view, the combination of ademetonine and taurine is warranted to examine its endothelial - and cardioprotective effect.

References

1. Bian K., Doursout M.F., Murad F. Vascular system: role of nitric oxide in cardiovascular diseases. *J. Clin. Hypertens. (Greenwich)*. №10 (2008): 304-310. [\[PubMed\]](#)[\[Full text\]](#)
2. Martynov A.I., Avetyan N.G., Akatova E.V., et al. Endothelial dysfunction in patients with hypertensive disease. *Cardiologia*. № 45(10) (2005): 101-104. [\[eLIBRARY\]](#)
3. Petrak O., Widimsky Jr. J., Zelinka T., et al. Biochemical markers of endothelial dysfunction in patients with endocrine and essential hypertension. *Physiol. Res*. №55 (2006): 597-602. [\[PubMed\]](#)[\[Full text\]](#)
4. Feletou M., Vanhoutte P.M. Endothelial dysfunction: a multifaceted disorder. *Am. J. Physiol. Heart. Circ. Physiol.* №291 (2006): H985-1002. [\[PubMed\]](#)[\[Full text\]](#)
5. Petuchov V.A. Endothelial dysfunction: the current state of the problem (on materials of the scientific Symposium). *Surgery. The application Consilium medicum*. №1 (2008): 3-11. [\[eLIBRARY\]](#)
6. Barbato J.E., Tzeng E. Nitric oxide and arterial disease. *J. Vasc. Surg.* №40 (2004): 187-193. [\[PubMed\]](#)
7. Belousov Y.B., Namsaraev J.N. The endothelial dysfunction is a cause of the atherosclerosis of the vessels

by arterial hypertension: the methods of the correction. *Pharmateca*. №6 (2000): 62-72. [\[Full text\]](#)

8. Zotova I.V., Zateychicov D.A., Sidorenko B.A. The synthesis of nitric oxide and the development of the atherosclerosis. *Cardiologia*. № 4 (2004): 58-67. [\[Full text\]](#)

9. Korokhin M.V., Nosov M.A., Pokrovsky M.V., et al. A comparative study of endothelial - and cardioprotective properties furostanol glycosides from cell culture plants of *Dioscorea Deltoidea* and 17 β -estradiol. *Kuban scientific medical Herald*. № 9 (2006): P. 137-140. [\[eLIBRARY\]](#)

10. Kochkarov V.I., Molchanova O.V., Pokrovskii M.V. et al. Simulation of endothelial dysfunction associated with hypestrogen-induced nitric oxide deficit. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. Vol. 5 (5) (2014): P. 1099-1102. [\[Scopus\]](#)[\[Full Text\]](#)

11. Hu J., Xu X., Yang J., Wu G., Sun C., Lv Q. Antihypertensive effect of taurine in rat. *AdvExp Med Biol*. Vol. 643 (2009): 75-84. [\[PubMed\]](#)

12. Xue W., Zhang M., Li J., Wu D., Niu L., Liang Y. Effects of taurine on aortic rings isolated from fructose-fed insulin resistance Sprague-Dawley rat are changed. *Cardiovasc Drugs Ther.* 22(6) (2008): 461-8. [\[PubMed\]](#)

13. Abebe W., Mozaffari M.S. Effect of taurine deficiency on adenosine receptor-mediated relaxation of the rat aorta. *Vascul Pharmacol.* 40(4) (2003): 219-228. [\[PubMed\]](#)

14. Kim S.Y., Hong S.W., Kim M.O., Kim H.S., Jang J.E., Leem J., Park I.S., Lee K.U., Koh E.H. S-adenosyl methionine prevents endothelial dysfunction by inducing heme oxygenase-1 in vascular endothelial cells. *MolCells*. 36(4) (2013): 376-84. [\[PubMed\]](#)

15. Artyushkova E.B., Sukhanov D. S., Dudka V. T. Hepato- and endothelioprotective action of runikhol and ademetonine in experimental liver anti-TB drugs in combination with alcohol. *N2* (2013): 45-49. [\[Abstract\]](#)

16. Pokrovskii M.V., Artyushkova E.B., Pokrovskaya T.G. Methods of experimental modeling of endothelial dysfunction. *Allergology and Immunology*. Vol. 9, № 3 (2008): 327. [\[eLIBRARY\]](#)

17. Belous A.S., Pokrovskii M.V., Pokrovskaya T.G. et al. Correction of endothelial dysfunction with impaza preparation in complex with enalapril and losartan during modeling of NO deficiency. *Bulletin of Experimental Biology and Medicine*. Vol. 148 (3) (2009): 511-513. [\[Scopus\]](#)[\[Full Text\]](#)

18. Pokrovskii M.V., Kochkarov V.I., Pokrovskaya T.G. et al. Comparative study of potential endothelioprotectors and impaza in modeled nitric oxide deficiency. *Bulletin of Experimental Biology and Medicine*. Vol. 148 (3) (2009): 514-517. [\[Scopus\]](#)[\[Full Text\]](#)

19. Pokrovskij M.V., Kochkarov V.I., Pokrovskaja T.G., et al. Methodical approaches for the quantitative estimation of development endothelial dysfunction at L-NAME-induced model of deficiency of nitric oxide in experiment. *Kuban scientific medical Bulletin*. №10 (2006): 72-77. [\[eLIBRARY\]](#)

20. Ziegler D., Hanefeld M., Ruhnau K.J. [et al.]

Treatment of symptomatic peripheral neuropathy with the anti-oxidant α -lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). *Diabetologia*. Vol. 38 (12) (1995): 1425–1433. [[PubMed](#)]

21. Lopez R.M., Ortiz C.S., Ruiz A. [et al.] Impairment of smooth muscle function of rat thoracic aorta in an endothelium-independent manner by long-term administration of N(G)-nitro-L-arginine methyl ester. *Fundam. Clin. Pharmacol.* №18(6) (2004): 669-677. [[PubMed](#)]

22. Kochkarov V.I., Molchanova O.V., Pokrovskii M.V. et al. Cardio protective action of thioctic acid combined with rosuvastatin in the combined hypoestrogen

and l-name-induced nitrogen oxide deficiency. *Research Journal of Pharmaceutical, Biological and Chemical Sciences*. Vol. 5(6) (2014): 1357-1360. [[Scopus](#)][[Full Text](#)]

23. Pokrovskaya, T.G. Combined pharmacological correction of metabolic pathway L-arginine/NO in the simulation of deficiency of nitric oxide [Text]: Author. Dis. ... *Doct. biol. Sciences: 14.00.25 / T.G. Pokrovskaya.* – Kursk, 2009. – 43 p. [[eLIBRARY](#)][[Full text](#)]

24. Denisyuk T.A., Lazareva G.A., Provotorov V.Yu., Shaposhnikov A.A. Endothelium and cardioprotective effects of HMG-Co-Areductase in combination with L-arginine in endothelial dysfunction modeling. *Research result: pharmacology and clinical pharmacology*. 2016. Vol.2, №1 (2): 4-8. [[Full text](#)]